Roche Raises Outlook Despite US Biosimilars, Sees Spark Buy By Year-End

Roche presented a strong first-half performance and raised its outlook again for the full year as sales continued to be driven by its portfolio of new medicines. It said its delayed takeover of Spark Therapeutics should happen by year-end.

Growth
Roche looking beyond cancer drugs as newer medicines spur growth • Source: Shutterstock

A strong performance by recently-launched drugs in this year’s second quarter allowed Roche on 25 July to beat market forecasts and to raise its 2019 full-year outlook for the second time this year, boosted by management’s rising confidence that it can ride out a wave of biosimilars entering the US market in the second half and continue growing earnings into 2020.

Roche said second-quarter group sales grew 9% at constant exchange rates, with the pharma division revenue up 11%, driven mainly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip